Anti-Human Cytokeratin 18 (Clone LDK18) – FITC

Anti-Human Cytokeratin 18 (Clone LDK18) – FITC

Product No.: C3461

- -
- -
Clone
LDK18
Target
Cytokeratin 18
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
Keratin 18, Keratin type I cytoskeletal 18
Isotype
Mouse IgG1 κ
Applications
IF
,
IHC
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Immunogen
Synthetic peptide of human keratin 18 .
Product Concentration
0.2 mg/ml
Formulation
This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Liquid
Storage and Handling
This Fluorescein conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Excitation Laser
Blue Laser (488 nm)
Additional Applications Reported In Literature ?
IHC,
IF,
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
LDK18 activity is directed against human Cytokeratin-18.
Background
Cytokeratin-18 (CK18 or KRT18) is a cytoskeletal, type I intermediate filament protein1 . CK18 is co-expressed with cytokeratin-8 (CK8), a type II intermediate filament protein 2 , and together they form a flexible heterodimeric intracellular scaffold to structure the cytoplasm. CK18 is important for apoptosis, mitosis, cell cycle progression, and cell signaling and is particularly abundant in the liver, where it comprises 5% of total liver protein 2, 3 . CK18 is vital to liver development; knockout mice lacking CK18 develop liver lesions and tumors 2 .

CK18 has clinical relevance to drug-induced liver disease and various cancers. During acute and chronic hepatocellular injury, necrotic cells passively release CK18 2 . The CK18 levels increase in serum and plasma 3 , and the degree of increase reflects the degree of necrotic hepatocellular injury and/or apoptosis 2 . Full length CK18 contains two caspase consensus sites, DALD and VEVD, that are targeted during apoptosis to facilitate cytoskeleton degradation. Both full length CK18 and the caspase cleaved fragments (ccCK18) are prognostic markers for drug-induced liver injury 2, 3 . In clinical settings, CK18 and ccCK18 fragments can be readily quantified by immunoassays, with full length CK18 particularly useful in diagnosing early-stage drug-induced liver injury 2 . Additionally, when pro- and anti-inflammatory cytokines are measured in combination with CK18 and ccCK18, the mechanism of hepatocellular injury (necrosis or apoptosis) can be determined.

CK18 also serves as a differential diagnostic marker in various cancers 1 . Additionally, changes in CK18 expression are associated with poor prognosis in a variety of cancers, including esophageal squamous cell carcinoma, renal cell carcinoma, lung cancer, and some adenocarcinomas.
Antigen Distribution
Cytokeratin-18 (CK18) is a structural marker protein specific to epithelial cells. CK18 is highly abundant in hepatocytes and cholangiocytes (epithelial cells of the bile duct). Additionally, CK18 is the main scaffold protein of keratinocytes produced by the intermediate filamentous filaments of most epithelial tissues (liver, lung, kidney, pancreas, gastrointestinal tract, mammary gland) as well as cancers that arise from these tissues. CK18 localizes to the cytoplasm and perinuclear region of the cell.
Ligand/Receptor
keratin 5, keratin 8, caspase 3, 14-3-3, TNF receptor II, plakophilin 2, EGF receptor, usherin
NCBI Gene Bank ID
UniProt.org
Research Area
Cell Biology
.
Cell Motility/Cytoskeleton/Structure
.
Neuroscience

References & Citations

1. Weng YR, Cui Y, Fang JY. Mol Cancer Res. 10(4):485-493. 2012.
2. Korver S, Bowen J, Pearson K, et al. Arch Toxicol. 95(11):3435-3448. 2021
3. McGill MR, Jaeschke H. Adv Pharmacol. 85:221-239. 2019.
4. Fulzele A, Malgundkar SA, Govekar RB, et al. J Proteomics. 75(8):2404-2416. 2012.
5. McElroy SP, Nomura T, Torrie LS, et al. PLoS Biol. 11(6):e1001593. 2013.
6. Zupancic T, Stojan J, Lane EB, et al. PLoS One. 9(6):e99398. 2014.
7. Cao S, Yu S, Chen Y, et al. J Biol Chem. 292(46):19122-19132. 2017.
8. Lee MJ, Kim JY, Lee SI, et al. Cell Tissue Res. 325(2):253-261. 2006.
IF
IHC
General Western Blot Protocol

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.